menu
    • menu
    [{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"MedTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Merger","leadProduct":"Nelitolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ MedTech","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ MedTech"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Oligodeoxynucleotide","moa":"Toll-like-9 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by TriSalus Life Sciences

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Gets WHO Approval for “Nelitolimod” Nonproprietary Name

                            Details : TriSalus SD-101 (Nelitolimod), a TLR-9 agonist, is in phase 1 trials for treating uveal melanoma with liver metastases, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma.

                            Product Name : SD-101

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : Nelitolimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Dat...

                            Details : SD-101, the Company’s investigational TLR9 agonist, is being delivered via TriNav® to selected sites, including tumors in the liver. It has the potential to reprogram and eliminate MDSCs.

                            Product Name : SD-101

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 16, 2023

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progr...

                            Details : SD-101, the company’s investigational TLR9 agonist, is being delivered via TriNav® to selected sites, including tumors in the liver. SD-101, a class C toll-like receptor 9 (“TLR9”) agonist.

                            Product Name : SD-101

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 15, 2022

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 C...

                            Details : The promising clinical data demonstrate that SD-101 delivered via TriNav® may support broad immune effects in liver tumors and eliminate myeloid-derived suppressor cells (“MDSC”).

                            Product Name : SD-101

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 21, 2022

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : MedTech

                            Deal Size : $110.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation

                            Details : TriSalus is developing SD-101, a class C toll-like receptor 9 (TLR9) agonist, that promotes T Cell infiltration, reduction of myeloid derived suppressor cells (MDSC) and broad immune activation to reverse immunosuppression in the liver and pancreas.

                            Product Name : SD-101

                            Product Type : Oligonucleotide

                            Upfront Cash : $110.0 million

                            November 14, 2022

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : MedTech

                            Deal Size : $110.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Ipilimumab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via P...

                            Details : SD-101, a potentially first-in-class, investigative TLR9 agonist, to reactivate the immune system within the liver and pancreas to enable more durable responses to other immunotherapeutics (e.g., checkpoint inhibitors) and improve patient outcomes.

                            Product Name : SD-101

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 05, 2022

                            Lead Product(s) : Nelitolimod,Ipilimumab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oligodeoxynucleotide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences Presents Data at AACR Showing Reduced Liver Tumor Burden from Toll-Receptor Agonists

                            Details : ODNs bind and activate TLR9 to initiate an immune response against certain cancer cells.2 TLR9 agonists (TLR9A) activate both the innate and adaptive immune systems, and play an important role in antiviral and anti-tumor immunity.

                            Product Name : ODN2395

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 14, 2021

                            Lead Product(s) : Oligodeoxynucleotide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxaliplatin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences Initiate Trial for Novel Delivery Technology

                            Details : Study to evaluate the Pressure-Enabled Drug Delivery™ approach combined with standard of care chemotherapy to enable deep tumor penetration and minimize dose-limiting toxicity.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 02, 2020

                            Lead Product(s) : Oxaliplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth